多替阿巴拉米片的疗效好吗？

The ingredients are dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. Three drugs are used for the treatment of HIV-1 infection. It is the only three-in-one compound drug containing dolutegravir. Dolutegra abalamib tablets have been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment for newly diagnosed AIDS patients. Today we are going to find out about the efficacy of Duotie Abalamid Tablets?

Dolutegra abalamib tablets have been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment for newly diagnosed AIDS patients. Comparing it with patients who failed the first-line regimen of the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir), doteabalamid (Inbec) has significantly fewer drug-resistant mutations than the other two drugs, making it less likely to develop drug resistance. Dote abalamib tablets are based on DTG, an integrase inhibitor, as the core drug. In the real world, antiviral treatment-naïve patients treated with DTG are better than RAL (Ascent), DRV/r (darunavir), EFV (efavirenz). ) and ATV/r (atazanavir) have a lower proportion of central nervous system-related (CNS) adverse events. Therefore, the drug safety of dolutea palamid tablets, which is based on DTG integrase inhibitors, has proven to be controllable.

Dolutegra (TRIUMEQ) has been approved in more than 100 countries, and has been recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment for newly diagnosed AIDS patients. Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the life spans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day, one tablet at a time on the Chinese market. The approval of TRIUMEQ fills this gap and meets the urgent need for convenient medication use by doctors and patients."

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). Existing research shows that one year (48 weeks) after HIV-infected patients were treated with TRIUMEQ, the viral load of 93% of the infected patients became negative.

The above is the content of the efficacy, I hope it can help you!